Invesaro

Stocks Comparison

Davita vs NewGenIvf: revenue, profit, margins and growth compared

Davita brought in $13.6B of revenue in fiscal 2025, NewGenIvf $23.7M in fiscal 2025. Revenue changed by +6.5% at Davita and +336.3% at NewGenIvf on the year before, so NewGenIvf grew faster. Davita kept 5.5% of its revenue as net profit, NewGenIvf 41.7%. Free cash flow was $1.3B at Davita and -$11.1M at NewGenIvf.

Side by side, latest fiscal year

DVANIVF
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$13.6B$23.7M
Revenue growth+6.5%+336.3%
Net income$746.8M$9.9M
Net margin5.5%41.7%
Free cash flow$1.3B-$11.1M
Free cash flow margin9.6%-46.7%
Earnings per share (diluted)$9.84$3.04
Cash$676.4M$758.6K
Debt$10.3Bn/a
Price to earnings18.1n/a
Market value$11.4B$3.3M
Dividend yieldn/an/a
Rank by revenue in sector#37 of 646 · Health care#425 of 646 · Health care

Over the years

Revenue
DVA FY2018: $11.4BDVA FY2019: $11.4BDVA FY2020: $11.6BDVA FY2021: $11.6BDVA FY2022: $11.6BDVA FY2023: $12.1BDVA FY2024: $12.8BDVA FY2025: $13.6BNIVF FY2021: $4.1MNIVF FY2023: $5.9MNIVF FY2023: $5.1MNIVF FY2024: $5.4MNIVF FY2025: $23.7MFY18FY19FY20FY21FY22FY23FY24FY25
DVA $13.6BNIVF $23.7M
Net income
DVA FY2018: $159.4MDVA FY2019: $811MDVA FY2020: $773.6MDVA FY2021: $978.5MDVA FY2022: $560.4MDVA FY2023: $691.5MDVA FY2024: $936.3MDVA FY2025: $746.8MNIVF FY2021: -$533NIVF FY2023: $458.7KNIVF FY2023: $130.2KNIVF FY2024: -$524.6KNIVF FY2025: $9.9MFY18FY19FY20FY21FY22FY23FY24FY25
DVA $746.8MNIVF $9.9M
Net margin
DVA FY2018: 1.4%DVA FY2019: 7.1%DVA FY2020: 6.7%DVA FY2021: 8.4%DVA FY2022: 4.8%DVA FY2023: 5.7%DVA FY2024: 7.3%DVA FY2025: 5.5%NIVF FY2021: -0.0%NIVF FY2023: 7.7%NIVF FY2023: 2.5%NIVF FY2024: -9.7%NIVF FY2025: 41.7%FY18FY19FY20FY21FY22FY23FY24FY25
DVA 5.5%NIVF 41.7%
Revenue growth
DVA FY2019: -0.1%DVA FY2020: +1.4%DVA FY2021: +0.6%DVA FY2022: -0.1%DVA FY2023: +4.6%DVA FY2024: +5.6%DVA FY2025: +6.5%NIVF FY2023: +44.3%NIVF FY2023: -13.6%NIVF FY2024: +5.8%NIVF FY2025: +336.3%FY19FY20FY21FY22FY23FY24FY25
DVA +6.5%NIVF +336.3%
Free cash flow
DVA FY2018: $784.5MDVA FY2019: $1.3BDVA FY2020: $1.3BDVA FY2021: $1.3BDVA FY2022: $961.1MDVA FY2023: $1.5BDVA FY2024: $1.5BDVA FY2025: $1.3BNIVF FY2021: $1.4MNIVF FY2023: $1.6MNIVF FY2023: -$1.8MNIVF FY2024: -$8.3MNIVF FY2025: -$11.1MFY18FY19FY20FY21FY22FY23FY24FY25
DVA $1.3BNIVF -$11.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about Davita and NewGenIvf

Which is bigger by revenue, Davita or NewGenIvf?

Davita is bigger by revenue: $13.6B in fiscal 2025, against $23.7M for NewGenIvf in fiscal 2025.

Which keeps more of its revenue as profit, Davita or NewGenIvf?

Davita had a net margin of 5.5% in fiscal 2025; NewGenIvf had 41.7% in fiscal 2025.

Which grew revenue faster, Davita or NewGenIvf?

In their latest fiscal years revenue changed by +6.5% at Davita and +336.3% at NewGenIvf.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies